The Guangzhou Liaison Office in Boston Hosts Sino-US BioTech Innovation Forum; Outlines Opportunities for Sino-US BioTech Cooperation & Development


BOSTON - Yesterday, the Sino-US BioTech Innovation Development Forum was held at District Hall in the Seaport District. The event was hosted by the Guangzhou Liaison Office in Boston, and consisted of representatives from the City of Boston, MassBIO, Sino-Singapore Guangzhou Knowledge City, and Guangzhou International BioTech Island, among the many other notable groups and attendees.

International Business Strategy Manager, Mayor's Office of Economic Development - Sarah Delude, offering opening remarks on behalf of the City of Boston.

International Business Strategy Manager, Mayor's Office of Economic Development - Sarah Delude, offering opening remarks on behalf of the City of Boston.

The forum began with opening statements by Sarah Delude from the City of Boston's Mayor's Office of Economic Development and Deputy Secretary of the CPC Working Committee of Guangzhou Development District, Minghe Tan, followed by presentations on Sino-Singapore Guangzhou Knowledge City and Guangzhou BioTech Island, highlighting opportunities for entrepreneurs and investors. The forum concluded with testimonials from entrepreneurs working with Guangzhou, and a panel discussion: How to Strengthen Sino-US Cooperation and Development in the Biotech Industry through Innovation & Integration.


Sino-Singapore Guangzhou Knowledge City

Covering an area of 123 square km, the Sino-Singapore Guangzhou Knowledge City (SSGKC) is one of the iconic projects of Sino-Singapore cooperation, The SSGKC project was jointly initiated by Guangdong and Singapore to serve as a model for economic transformation and industrial upgrading. SSGKC is positioned as a unique, vibrant, and sustainable city that is highly attractive to both talents and knowledge-based industries. In the next 20 years, SSGKC is expected to house a resident population of over 500,000 and will provide the ideal environment for work, leisure, learning, and life.


  • Located in the northeast of Guangzhou
  • Only 25 km from Guangzhou's Baiyun Airport
  • Only 35 km from Guangzhou's city center
  • Features high-speed metros, subways, rails, and expressways

key industries 

  • Next-Generation ICT
  • Artificial Intelligence
  • Biotech & Healthcare
  • New Energy & Clean Technology
  • New Materials
  • Science & Education Services 

Public Amenities

  • Top-notch Schools & Educational Facilities 
  • Neighborhood Centers
  • Integrated Family Service Centers
  • Pedestrian and Cycling Paths

Residential and commercial amenities 

  • Dynamic Housing Options
  • Waterfront Living
  • Riverside Dining, Entertainment, and Retail District


Guangzhou International BioTech Island

Guangzhou International BioTech Island is a beautiful, lush enclave dedicated to the development of world-class innovation in the life sciences. Located in the heart of the city of Guangzhou, the island will feature 1.8 million square meters of space, with over 1.4 million dedicated to R&D alone. Guangzhou International BioTech Island has several main advantages:

Excellent Location

The island's location is ideal for supporting the life sciences industry. Directly to the south is Guangzhou's Higher Education Mega Center, which features 10 different universities with over 120,000 students. To the north of the island lie Guangzhou's Central Business District and the Pazhou Exhibition Center, which provides easy access to financing and conferences. 

Government Policy Support

Administratively, the island lies within the Guangzhou Development District, which gives the island some of the best supporting policies for innovation and economic development in the entire city.

International Presence & Cooperation

Several international cooperation platforms have been built on the island, including China-Israel, China-EU, China-UK, China-USA, and China-Cuba cooperative bases. 

Eco-Friendly Environment

The island has one of the most eco-friendly environments in the entire city, with a green rate of over 47%, and a scenic location in the middle of the beautiful Pearl River. 


Panel Discussion: 


As noted by panel discussion moderator Dr. Jason Wen, Director of the Office of Technology Transfer and Licensing at Boston College, the key to Sino-US biotech collaboration lies within a fundamental exchange: the United States' wealth of biotech innovations and talent, and China's enormous market and eager investors.

This key idea from the discussion was given further support by TechCode Boston Deputy General Manager, Anthony DeOrsey, who provided three main reasons why U.S-based biotech companies should strongly consider going to China:

  • C-FDA Approval Easier - In China, the process for bringing a potential drug or biotech innovation to market is easier than in the United States, allowing for a faster to-market time.
  • Government Support - There is a currently a huge push by all levels of the Chinese government to bring biotech innovation to China, and many generous policies have been put in place to support and encourage biotech innovators and researchers to settle in China and bring their products to market. 
  • Favorable Investment Environment - Many state and private-led investment firms and venture capital firms have been set up, precisely to target biotech innovation. This, combined with more lenient business regulations in general, make China an ideal place to go for biotech companies. 



Overall, the event proved to be a success, with many new connections and relationships formed between key stakeholders in both US and Chinese-based organizations, and we are excited to be able to promote such partnerships on a greater scale in the future. As Sarah Delude put it best:

"Boston has a highly developed, mature biotech industry, a steady supply of talented, highly-skilled labor, and a favorable investment environment. Since establishing relations with the city of Guangzhou in 2015, we look forward to strengthening and deepening our relationship, pursuing further cooperation and partnerships for mutual benefit."